3 ms·
> The cost of regulatory approval is high, but that's justified because the economic cost of a bad or even just ineffective drug piles up very quickly I wonder
by kalleboo 10y ago
> The cost of regulatory approval is high, but that's justified because the economic cost of a bad or even just ineffective drug piles up very quickly
I wonder what the result would be of vastly reducing regulatory approval requirements, but in exchange giving pharmaceutical companies unlimited liability. So, sure, put that poorly-tested drug out there, but every person who has horrifying side-effects is going to sue you for millions
- harryh 10y agoFor one, drug companies would probably start making people sign liability waivers before agreeing to sell them a lot of newer drugs.
- rayiner 10y ago> I wonder what the result would be of vastly reducing regulatory approval requirements, but in exchange giving pharmaceutical companies unlimited liability I don't think lawsuits are the best "first line of defense" for protecting consumers against harmful drugs. Because the usual measure of damages is the cost of harm, the actual recovery (once discounted by litigation risk and diminished by legal fees), is a fraction of the cost of the harm. That discount is particularly significant in medical cases, because proving causation is very difficult (how do you know that this drug caused your dad's heart attack instead of the three others he was taking?). Moreover, drug-related litigation these days relies heavily on the factual record developed by clinical trials and FDA investigations. Class action lawsuits are often precipitated by an FDA action. E.g. major litigation like Fen-Phen and Vioxx, that netted tens of billions of dollars in recovery for consumers, were kicked off by FDA recalls. Individual litigants are poorly positioned to develop the scientific record necessary to support a lawsuit.